patients with diffuse systemic sclerosis (DSS) and 10 patients with circumscribed scleroderma or morphoea (M) were treated with increasing doses to a routine maintenance 'low-dose' of 300 mg daily of Dpenicillamine (DP) (Tio et al. 1973 ). Increase of the dosage up to 3 g daily of DP or reduction of dosage occurred at the outpatient department.
The following parameters were used: clinical complaints (including Raynaud's phenomena), qualities of the skin, (numerically expressed), maximal flexion and extension of the fingers, elbow and shoulder joints, pulmonary function tests, motility of the digestive tract by roentgencinematography, X-ray pictures of the digits, EMG, ratio of soluble/insoluble collagen (Tio et al. 1973) , immunoglobulins, antinuclear antibody and immunofluorescence of the skin. The results are summarized in Table 1 . In DSS, improvement on 'low-dose' DP was observed retrospectively in all cases of the socalled 'white' type. This type shows white-cold skin over the fingers, often extending to the hands and lower arms and, in the only rapidly progressing case, even over the trunk. The little finger and elbow or shoulder joints may show contractures. Raynaud's phenomena were always present. Correlated with the speed and degree of improvement on DP, this form could, according to the degree of' induration, be subdivided clinically into three grades according to subtype. Grade 1 is more cedematous (0), grade 2 is moderate (I), 'Present address: Lieven de Keystraat 72, Rotterdam-14, The Netherlands and grade 3 is hard scirrhous (Sc). Thus, the 0 form could show rapid initial signs of improvement, sometimes even starting within a week, while the effective dose could also be lower. On the other hand, the skin of the scirrhous (Sc) type started to soften only after more than a year of uninterrupted treatment. Similar subtyping can be applied to the whole or parts of the lesions of morphcea.
Improvement of Raynaud's phenomena trailed far behind the amelioration of the skin and varied according to severity: in minor cases pain may disappear completely, but in the severest case (pilot case I, Tio et al. 1973) only decrease of the daily frequency in attacks and of the pain was spontaneously reported. None of the patients lost the bluish after-hue.
A second, therapeutically and clinically entirely different type could clearly be distinguished. This type is apparently either completely resistant to DP therapy or may slowly improve after more than a year of uninterrupted treatment with a 'high' dose, namely 3 g of DP daily. The fresh red and warm 'acute' skin symptoms subside gradually with normalization of the skin temperature and the appearance of dull brown pigmentation. The relaxation of contractures of the elbows and shoulders occurred several months later. Raynaud's phenomena were conspicuously absent. In one case the high dose could be reduced, even down to 650 mg daily, correlated with improvement in clinical symptoms with no reverse in progress.
A combined, so-called 'mixed' type, as also observed by Moynahan (personal communication), exhibits features of the white type on the acral parts, including Raynaud's phenomena, and red-warm symptoms on more proximal segments. (An identical 'mixed' type was observed in one morphoea patient.) In the mixed DSS type the acral white symptoms, including Raynaud's phenomena, clearly improved on 'low' dose DP while the more proximal red-warm parts and contracture of the elbows continues to progress. After more than a year of uninterrupted 'high' dose (3 g daily) DP, the 'acute' symptoms subsided, followed by relaxation of the contractures of the elbows. The dosage of DP could then be reduced accordingly.
Comments
Our results with DP therapy for the sclerodermas clearly distinguished two different types of response with distinct clinical symptoms. The so-called 'penicillamine types' roughly correlate with some major older and recent classifications (see Table 2 ).
It is clear, however, that the types and subtypes rather than duration or progression of the Table 2 Classifications Tio (1974, unpublished) Hilton Fagge (1864) Winkelmann (1976) disease are decisive for estimating the effective dose of DP. Typing and subtyping of the sclerodermas would appear to help clinicians and laboratory research workers to obtain comparable results because DP is also known to interfere in collagen metabolism.
In scleroderma a collapse of regulatory factors in collagen metabolism is suggested (Grant & Prockop 1972) : either there is an increase in the synthesis of collagen because of failure of some mechanism for feedback inhibition or, alternatively, there is a decrease of specific collagenases responsible for the degradation of collagen. With regard to the above assumption the following findings could be relevant: in 8 'acute' (red) cases out of a total of 25 systemic sclerosis cases increase of protocollagen proline hydroxylase (PPH) (Uitto 1971 ) was demonstrated (as compared to our 5 red-warm and mixed cases out of a total of 22 DSS patients). Subsequently, in 7 out of 12 systemic sclerosis patients, who, like our white type, showed involvement of the fingers, reduced quantities of collagenase were found (Brady 1975 ) (in our series there were 17 white type cases in a total of 22 patients). Although DP inhibits PPH in vitro it does not affect PPH in intact ceils, such as in bone culture (Uitto 1970) , nor did DP affect the elevated PPH enzyme activity in 2 scleroderma patients . It is known that DP does not penetrate, or only minimally penetrates, the cell membrane (Nimni and Chou, personal communications, 1976) . It is therefore tempting to consider the hypothesis that there is a preponderance of enhanced (intracellular) PPH activity in the red-warm type/area and an extracellular blocking process, caused by reduced collagenase activity in the white types. The location of the main biochemical disturbance and cell membrane barrier may (partially) account for the efficacy of 'low' dose DP in the white type while the red type is rather resistant even to 'high-dose' DP.
